Shares last traded at $0.17 which is slightly below $0.18, the 50 day moving average and a great deal lower than the 200 day moving average of $0.31. The 50 day moving average went down $-0.01 or -6.7731% and the 200 day average was down $-0.14. Trading was light with 92K shares changing hands in the last trading session. Overall, volume was down 81.84% under the stocks normal daily volume.
Traders are more bullish on Argos Therapeutics, Inc. of late if you take into consideration the downtick in short interest. The company saw a fall in short interest between September 15, 2017 and September 29, 2017 of -9.71%. Short shares decreased 368,841 over that period. The days to cover decreased to 1.0 and the percentage of shorted shares was 0.08% on September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (ARGS). Tower Research Capital LLC (trc) reduced its stake by shedding 2,221 shares a decrease of 31.1%. Tower Research Capital LLC (trc) claims 4,914 shares valued at $2,000. The total value of its holdings decreased 33.3%. Hightower Advisors, LLC augmented its holdings by buying 5,500 shares an increase of 20.7% in the quarter. Hightower Advisors, LLC owns 32,071 shares with a value of $11,000. The value of the position overall is down by 0.0%.
As of quarter end Cutler Group LP had bought a total of 1,300 shares growing its position 216.7%. The value in dollars went from $0 to $0 a change of nan% since the last quarter. Meeder Asset Management Inc grew its position by buying 10,172 shares an increase of 572.1% as of 09/30/2017. Meeder Asset Management Inc now holds 11,950 shares worth $2,000. The total value of its holdings increased 100.0%.
As of the last earnings report the EPS was $-1.49 and is expected to be $-1.19 for the current year with 54,974,000 shares currently outstanding. Analysts expect next quarter’s EPS will be $-0.20 and the next full year EPS is anticipated to be $-0.48.
Argos Therapeutics, Inc. (Argos), launched on May 8, 1997, is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. Its product candidates include AGS-003 and AGS-004..